Less Ads, More Data, More Tools Register for FREE

Indivior's opioid addiction sprat approved by FDA

Tue, 23rd May 2023 07:48

(Sharecast News) - US health regulators have approved Indivior's Opvee nasal spray treatment for opiod addiction, the company said on Tuesday.

The drug will help combat overdoses caused by fentanyl and other opioids dtiving America's drug crisis. Opvee works by blocking the effects of opioids in the brain, which can restore breathing and blood pressure in people who have recently overdosed.

"Opvee's Food and Drug Administration's approval represents a significant achievement in the development of new treatment options to address today's era of opioid overdoses that are driven by powerful synthetic opioids, such as fentanyl," said chief executive Mark Crossley.

Reporting by Frank Prenesti for Sharecast.com

Related Shares

More News
23 May 2024 12:29

IN BRIEF: Indivior reconfirms 2024 outlook amid NY-listing decision

Indivior PLC - Chesterfield, Virginia-headquartered pharmaceutical maker - Reconfirms financial guidance for 2024 ahead of analyst 'teach-in' event in...

16 May 2024 15:46

UK shareholder meetings calendar - next 7 days

3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

2 May 2024 13:48

UK shareholder meetings calendar - next 7 days

25 Apr 2024 09:23

Indivior shares down despite profit boost on planned shift to New York

(Alliance News) - Indivior PLC on Thursday saw its shares fall despite reporting a quarterly uptick in profit, as it announced plans to switch its lis...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.